NEOP

(redirected from Neoprobe Corporation)
AcronymDefinition
NEOPNeoprobe Corporation (stock symbol)
NEOPNew Employee Orientation Program (various locations)
NEOPNear Earth Object Program
NEOPNew England Order of Protection
NEOPNuclear Explosive Operating Procedure
NEOPNuclear Energy of the Populace (Austria)
NEOPNo Expectation of Privacy (song)
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
5 January 2012 - Neoprobe Corporation (NYSEAMEX:NEOP), a US-based biomedical company specialised in oncology products, said on Thursday that it has secured up to USD10m (EUR7.7m) in debt financing from Hercules Technology II LP, a fund managed by Hercules Technology Growth Capital Inc (NASDAQ:HTGC).
Neoprobe Corporation (OTCBB: NEOP), Dublin, Ohio, a diversified developer of innovative oncology surgical and diagnostic products, has announced that it expects to report revenue of approximately $2.6 million and $5.3 million for the second quarter and year-to-date in 2010, respectively.
Neoprobe Corporation (Nasdaq/NMS:NEOP), Dublin, Ohio, has signed an exclusive distribution agreement with Century Medical, Inc., Tokyo, Japan, to market and distribute its gamma detection products.
20 October 2011 - US Neoprobe Corporation (AMEX:NEOP) said yesterday that the US Food and Drug Administration (FDA) had accepted for review its New Drug Application (NDA) for Lymphoseek (tilmanocept).
(AEP602) BRENT LARSON - NEOPROBE CORPORATION (NEOP).
8 September 2011 - US biomedical company Neoprobe Corporation (NYSE:NEOP) said yesterday that the European Medicines Agency (EMA) had issued a positive scientific advice on the development of RIGScan CR, the company's radiopharmaceutical for the detection of colorectal cancer.
11 August 2011 - US Neoprobe Corporation (NYSE: NEOP) said yesterday it has filed a New Drug Application (NDA) for Lymphoseek (tilmanocept) with the US Food and Drug Administration (FDA).
8 March 2011 - US oncology surgical and diagnostic products developer Neoprobe Corporation (AMEX: NEOP) said yesterday it has completed a successful pre-IND meeting with the US Food and Drug Administration (FDA) on the development of RIGScan CR, its radiopharmaceutical for the detection of colorectal cancer tumours.
11 December 2009 - US biomedical company Neoprobe Corporation (OTC: NEOP) said today that researchers who participated in the breast cancer arm of a Phase III clinical evaluation of Lymphoseek presented data from their clinical experience at the International San Antonio Breast Cancer Symposium.